Literature DB >> 28166668

Association between plasma proprotein convertase subtisilin/kexin type 9 concentration and coronary artery calcification.

Xi Zhao1, Hui-Wen Zhang1, Sha Li1, Yan Zhang1, Rui-Xia Xu1, Cheng-Gang Zhu1, Na-Qiong Wu1, Yuan-Lin Guo1, Ping Qing1, Xiao-Lin Li1, Geng Liu1, Qian Dong1, Jing Sun1, Jian-Jun Li1.   

Abstract

Background Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to be related to several risk factors and diseases such as inflammatory markers and coronary artery disease. The aim of present study was to investigate whether plasma PCSK9 concentration was associated with coronary artery calcification. Methods A total of 403 consecutive untreated patients with angina-like chest pain, who received electron beam computed tomography, were enrolled and a coronary artery calcification score (CACS) was also measured. The baseline clinical characteristics were collected and blood sample was taken after 12-h fasting. The plasma PCSK9 concentrations were determined by ELISA in all patients, and the relationship between plasma PCSK9 concentrations and CACS was investigated. Results Patients with coronary artery calcification (CACS > 0) had significant higher plasma PCSK9 concentrations compared with those (CACS = 0) without coronary artery calcification (258.58 ± 69.53 ng/mL vs. 202.53 ± 52.17 ng/mL, P < 0.001). Patients with highest PCSK9 concentrations had the highest CACS. Multivariable linear regression analysis suggested that PCSK9 was independently associated with coronary artery calcification ( P = 0.002) after adjusting for traditional cardiovascular risk factors. Furthermore, the area under the curve for the plasma PCSK9 concentration in predicting coronary artery calcification was 0.736 (95% CI: 0.687-0.785, P < 0.001), with a sensitivity of 66% and specificity of 70%. Conclusion A positive association between plasma PCSK9 concentration and coronary artery calcification in untreated patients with angina-like chest pain was observed in our study, suggesting that further investigation may be needed in order to confirm our primary findings and explore the clinical implications.

Entities:  

Keywords:  PCSK9; coronary artery calcification; coronary artery calcification score; electron beam computed tomography

Mesh:

Substances:

Year:  2017        PMID: 28166668     DOI: 10.1177/0004563217695351

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  10 in total

Review 1.  An integrated approach to coronary heart disease diagnosis and clinical management.

Authors:  Teresa Infante; Ernesto Forte; Concetta Schiano; Carlo Cavaliere; Carlo Tedeschi; Andrea Soricelli; Marco Salvatore; Claudio Napoli
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 2.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

3.  Response: Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome (Diabetes Metab J 2018;42:207-14).

Authors:  Sung Woo Kim; Keun Gyu Park
Journal:  Diabetes Metab J       Date:  2018-08       Impact factor: 5.376

4.  The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy.

Authors:  Yuichi Ikegami; Ikuo Inoue; Kaiji Inoue; Yuichi Shinoda; Shinichiro Iida; Seiichi Goto; Takanari Nakano; Akira Shimada; Mistuhiko Noda
Journal:  NPJ Aging Mech Dis       Date:  2018-06-22

5.  Circulating Proprotein Convertase Subtilisin/Kexin type 9 level independently predicts incident cardiovascular events and all-cause mortality in hemodialysis black Africans patients.

Authors:  François-Pantaléon Musungayi Kajingulu; François Bompeka Lepira; Aliocha Natuhoyila Nkodila; Jean-Robert Rissassy Makulo; Vieux Momeme Mokoli; Pepe Mfutu Ekulu; Justine Busanga Bukabau; Yannick Mayamba Nlandu; Augustin Luzayadio Longo; Nazaire Mangani Nseka; Laura Labriola; Ernest Kiswaya Sumaili
Journal:  BMC Nephrol       Date:  2022-03-30       Impact factor: 2.388

6.  Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease.

Authors:  Fei Gao; Yue Ping Li; Xiao Teng Ma; Zhi Jian Wang; Dong Mei Shi; Yu Jie Zhou
Journal:  Front Cardiovasc Med       Date:  2022-05-06

Review 7.  Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.

Authors:  Simon Glerup; Rainer Schulz; Ulrich Laufs; Klaus-Dieter Schlüter
Journal:  Basic Res Cardiol       Date:  2017-04-24       Impact factor: 17.165

8.  Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina.

Authors:  Chiara Caselli; Serena Del Turco; Rosetta Ragusa; Valentina Lorenzoni; Michiel De Graaf; Giuseppina Basta; Arthur Scholte; Raffaele De Caterina; Danilo Neglia
Journal:  Cardiovasc Diabetol       Date:  2019-10-31       Impact factor: 9.951

9.  Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.

Authors:  Ye-Xuan Cao; Jing-Lu Jin; Di Sun; Hui-Hui Liu; Yuan-Lin Guo; Na-Qiong Wu; Rui-Xia Xu; Cheng-Gang Zhu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  J Transl Med       Date:  2019-11-11       Impact factor: 5.531

Review 10.  Effects of Eicosapentaenoic Acid on Arterial Calcification.

Authors:  Yukihiro Saito; Kazufumi Nakamura; Hiroshi Ito
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.